Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.
Healthcare solutions provider Solventum (NYSE:SOLV) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 2.2% year on year to ...
Healthcare solutions provider Solventum (NYSE:SOLV) will be reporting results this Wednesday after market hours. Here’s what you need to know. Solventum beat...
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Since January 2026, Solventum has been in a holding pattern, posting a small loss of 2.2% while floating around $77.29. The stock also fell short of the S&P ...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realiz...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - div...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
While Solventum has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Spin-offs and mergers can lead to major movement for share prices, but accessing these scenarios can be challenging for investors; these ETFs can help.
Solventum’s first quarter results reflected the impact of ongoing transformation initiatives, new product launches, and portfolio adjustments. Management poi...
Healthcare solutions provider Solventum (NYSE:SOLV) reported Q1 CY2026 results topping the market’s revenue expectations, but sales fell by 3% year on year t...
